Graviti Pharmaceuticals Private Limited

Graviti Pharmaceuticals Private Limited, established on December 27, 2012, is a privately held pharmaceutical company headquartered in Hyderabad, Telangana, India. The company specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Its Corporate Identification Number (CIN) is U24232TG2012PTC085058.

As of September 1, 2025, Graviti Pharmaceuticals employed approximately 841 individuals. The company's authorized capital stands at ₹500 crore, with a paid-up capital of ₹490 crore, reflecting a 98% paid-up ratio. Graviti Pharmaceuticals operates with a strong focus on research and development, aiming to provide high-quality, affordable pharmaceutical products globally.

Graviti Pharmaceuticals operates state-of-the-art manufacturing facilities in Hyderabad, Telangana, India. These facilities are equipped to produce a wide range of finished pharmaceutical formulations, including oral solid dosage forms, specialty formulations, and advanced drug delivery systems. The company adheres to stringent manufacturing standards, ensuring compliance with global regulatory requirements.

The leadership team at Graviti Pharmaceuticals includes:

• Dheeraj Kumar Gorukanti: Managing Director, appointed on December 27, 2012.

• Suguna Raman: Director, appointed on December 27, 2012.

• Jaganmohan Rao Boinapalli: Additional Director, appointed on March 24, 2025.

• Murali Sanyasi Rao Vasireddy Vasudeva: Company Secretary, appointed on October 6, 2019.

Graviti Pharmaceuticals has established a significant presence in regulated markets, including the United States, Europe, the United Kingdom, Australia, and Japan. The company has received approvals from the U.S. Food and Drug Administration (FDA) and complies with Good Manufacturing Practices (GMP) standards set by the World Health Organization (WHO). These certifications enable Graviti Pharmaceuticals to market its products in these regions, ensuring adherence to stringent quality and safety standards.

Graviti Pharmaceuticals has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's adherence to WHO prequalification standards facilitates access to these regions, allowing it to offer affordable and high-quality pharmaceutical products to a broader patient base.

Graviti Pharmaceuticals demonstrates a diversified geographic strategy by exporting to multiple regions, including the United States, Europe, the United Kingdom, Australia, Japan, Africa, Latin America, and Southeast Asia. This approach mitigates concentration risk and positions the company to leverage growth opportunities across various markets. The strategic direction focuses on expanding its global footprint while maintaining compliance with international regulatory standards.

Graviti Pharmaceuticals has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), enabling the export of its pharmaceutical products to the United States. The company has filed Abbreviated New Drug Applications (ANDAs) for various products, demonstrating its commitment to providing affordable generic medications. Additionally, Graviti Pharmaceuticals has submitted Drug Master Files (DMFs) to the FDA, ensuring transparency and compliance with regulatory requirements. The company's facilities have undergone FDA inspections, with recent audits resulting in zero 483 observations, reflecting a high standard of manufacturing practices.

Graviti Pharmaceuticals adheres to Good Manufacturing Practices (GMP) as outlined by the World Health Organization (WHO) and the European Union (EU). The company's manufacturing facilities are WHO-GMP certified, ensuring that its products meet international quality standards. Graviti Pharmaceuticals is also in the process of obtaining EU GMP certificates, further expanding its market access in Europe.

In India, Graviti Pharmaceuticals holds manufacturing licenses issued by the Central Drugs Standard Control Organisation (CDSCO), authorizing the production of pharmaceutical formulations. The company complies with state drug controller approvals and has obtained export No Objection Certificates (NOCs), facilitating the export of its products to various international markets.

As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Graviti Pharmaceuticals by regulatory authorities. The company's commitment to quality and compliance is evident in its recent FDA inspections, which resulted in zero 483 observations, underscoring its adherence to stringent manufacturing standards.

Graviti Pharmaceuticals operates in a competitive landscape, with key competitors in overlapping therapeutic categories. The company's top five exported products—Gabapentin, Calcium, Atorvastatin, Furosemide, and Citalopram—are widely produced by various pharmaceutical companies. Graviti Pharmaceuticals holds a 3.1% market share in Gabapentin, 2.8% in Calcium, 2.2% in Atorvastatin, 20.3% in Furosemide, and 2.1% in Citalopram. The company's portfolio concentration, with the top five products accounting for 94.7% of total exports, indicates a focused approach in its product offerings.

Graviti Pharmaceuticals differentiates itself through its commitment to quality, innovation, and affordability. The company invests significantly in research and development, enabling the creation of next-generation therapies and high-impact pharmaceutical solutions. Its adherence to Good Manufacturing Practices (GMP) and Quality by Design (QbD) principles ensures product integrity and regulatory compliance at every stage. Graviti Pharmaceuticals' focus on responsible partnerships and a culture of value further strengthens its competitive position in the global pharmaceutical market.

Graviti Pharmaceuticals' current strategic direction emphasizes the production of generic pharmaceuticals, with a focus on oral solid dosage forms, specialty formulations, and advanced drug delivery systems. The company's future outlook includes expanding its product portfolio to include specialty drugs and biosimilars, enhancing its position in the global pharmaceutical market. Graviti Pharmaceuticals also aims to strengthen its contract development and manufacturing organization (CDMO) services, offering comprehensive solutions to meet the evolving needs of its clients.

Graviti Pharmaceuticals has demonstrated a strong track record in manufacturing and exporting pharmaceutical products. The company's total export value of $101.1 million USD across 4,470 shipments reflects consistent performance in international markets. The top five products—Gabapentin, Calcium, Atorvastatin, Furosemide, and Citalopram—account for a significant portion of the company's export portfolio, indicating a focused and reliable supply chain. Graviti Pharmaceuticals' adherence to global regulatory standards and its commitment to quality further enhance its reliability as a supplier.

Importers should verify the following certifications to ensure compliance and product quality:

• FDA Registration: Confirm that Graviti Pharmaceuticals' manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA).

• WHO-GMP Certification: Ensure that the company holds Good Manufacturing Practices (GMP) certification from the World Health Organization (WHO).

• EU GMP Certification: Verify that Graviti Pharmaceuticals possesses Good Manufacturing Practices (GMP) certification from the European Union (EU).

• ISO Certification: Check for International Organization for Standardization (ISO) certifications related to quality management systems.

These certifications can typically be verified through the respective regulatory bodies' official websites or by contacting Graviti Pharmaceuticals directly.

When conducting due diligence on Graviti Pharmaceuticals, consider the following steps:

• Verify Regulatory Approvals: Confirm that the company's manufacturing facilities are registered with relevant regulatory authorities, such as the FDA, WHO, and EU.

• Assess Financial Health: